Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 18/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16927790 | 1.00 | ALOX5 (0.63) | ALOX5MEN1ALDH1A1TP53CYP1A2 | |
| SCHEMBL7638013 | 0.84 | ALOX5 (0.54) | ALOX5 | |
| SCHEMBL1894728 | 0.75 | ALOX5 (0.44) | ALOX5 | |
| SCHEMBL6436758 | 0.75 | ALOX5 (0.44) | ALOX5 | |
| SCHEMBL9208627 | 0.72 | ALOX5 (0.62) | ALOX5MEN1ALDH1A1TP53CYP1A2 | |
| SCHEMBL9208616 | 0.72 | ALOX5 (0.62) | ALOX5MEN1ALDH1A1TP53CYP1A2 | |
| SCHEMBL8357228 | 0.69 | ALOX5 (0.64) | ALOX5MEN1ALDH1A1TP53CYP1A2 | |
| SCHEMBL2880522 | 0.69 | ALOX5 (0.64) | ALOX5MEN1ALDH1A1TP53CYP1A2 | |
| SCHEMBL13696966 | 0.67 | ALOX5 (0.61) | ALOX5 | |
| SCHEMBL1807930 | 0.66 | ALOX5 (1.00) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121440-A1 | ACNE TREATMENT | ZOUBOULIS CHRISTOS C (DE) | 2021-04-29 | — | — | US | claimed |
| US-20190298689-A1 | ACNE TREATMENT | ZOUBOULIS CHRISTOS C (DE) | 2019-10-03 | — | — | US | claimed |
| US-20170296509-A1 | ACNE TREATMENT | ZOUBOULIS CHRISTOS C (DE) | 2017-10-19 | — | — | US | claimed |
| US-20150272926-A1 | ACNE TREATMENT | ZOUBOULIS CHRISTOS C (DE) | 2015-10-01 | — | — | US | claimed |
| US-20140066494-A1 | ACNE TREATMENT | ZOUBOULIS CHRISTOS C (DE) | 2014-03-06 | — | — | US | claimed |
| US-20130085174-A1 | ACNE TREATMENT | ZOUBOULIS CHRISTOS C (DE) | 2013-04-04 | — | — | US | claimed |
| US-20110086907-A1 | ACNE TREATMENT | ZOUBOULIS CHRISTOS C | 2011-04-14 | — | — | US | claimed |
| CN-101277614-A | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway | ACCELALOX INC (US) | 2008-10-01 | — | — | CN | claimed |
| EP-1947942-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | Accelalox, Inc. (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2007022427-A9 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2007-10-18 | — | — | WO | claimed |
| WO-2007022427-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-7132441-B2 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. (US) | 2006-11-07 | — | — | US | claimed |
| EP-1385505-B1 | ACNE TREATMENT WITH LIPOOXIGENASE INHIBITORS | ZOUBOULIS CHRISTOS (DE) | 2006-07-05 | — | — | EP | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| US-20040259920-A1 | Lipoxygenase inhibitors as antiinflammatory agents for treatment of acne by mouth or topical application | ZOUBOULIS CHRISTOS C (DE) | 2004-12-23 | — | — | US | claimed |
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. | 2002-10-03 | — | — | US | claimed |
| EP-0888127-B1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2001-12-12 | — | — | EP | claimed |
| US-6136839-A | USING A SULFONE OR SULFOAMIDE BENZENE COMPOUND | G. D. SEARLE & CO. (US) | 2000-10-24 | — | — | US | claimed |
| CN-101277614-A | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway | ACCELALOX INC (US) | 2008-10-01 | — | — | CN | disclosed |
| US-6136839-A | USING A SULFONE OR SULFOAMIDE BENZENE COMPOUND | G. D. SEARLE & CO. (US) | 2000-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | ALOX5, ALOX15B, ALOX15 | ALOX5 1/4885MEN1 4610/4885ALDH1A1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.